Journal
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Volume 308, Issue 4, Pages R227-R237Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpregu.00276.2014
Keywords
kidney; calcium blocker; calcium antagonist; blood vessels; cardiovascular disease
Categories
Funding
- Danish Medical Research Council [11-107552]
- Danish Heart Foundation [11-04-R84-A3492-22663]
- Aase and Ejnar Danielsens Foundation
- Novo Nordisk Fonden [NNF14OC0013273] Funding Source: researchfish
Ask authors/readers for more resources
Over the years, it has been discussed whether T-type calcium channels Ca(v)3 play a role in the cardiovascular and renal system. T-type channels have been reported to play an important role in renal hemodynamics, contractility of resistance vessels, and pacemaker activity in the heart. However, the lack of highly specific blockers cast doubt on the conclusions. As new T-type channel antagonists are being designed, the roles of T-type channels in cardiovascular and renal pathology need to be elucidated before T-type blockers can be clinically useful. Two types of T-type channels, Ca(v)3.1 and Ca(v)3.2, are expressed in blood vessels, the kidney, and the heart. Studies with gene-deficient mice have provided a way to investigate the Ca(v)3.1 and Ca(v)3.2 channels and their role in the cardiovascular system. This review discusses the results from these knockout mice. Evaluation of the literature leads to the conclusion that Ca(v)3.1 and Ca(v)3.2 channels have important, but different, functions in mice. T-type Ca(v)3.1 channels affect heart rate, whereas Ca(v)3.2 channels are involved in cardiac hypertrophy. In the vascular system, Ca(v)3.2 activation leads to dilation of blood vessels, whereas Ca(v)3.1 channels are mainly suggested to affect constriction. The Ca(v)3.1 channel is also involved in neointima formation following vascular damage. In the kidney, Ca(v)3.1 regulates plasma flow and Ca(v)3.2 plays a role setting glomerular filtration rate. In conclusion, Ca(v)3.1 and Ca(v)3.2 are new therapeutic targets in several cardiovascular pathologies, but the use of T-type blockers should be specifically directed to the disease and to the channel subtype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available